中华劳动卫生职业病杂志
中華勞動衛生職業病雜誌
중화노동위생직업병잡지
CHINESE JOURNAL OF INDUSTRIAL HYGIENE AND OCCUPATIONAL DISEASES
2011年
10期
751-755
,共5页
陈玲珍%刘薇薇%陈嘉榆%余卫%叶更新%詹昱%巫进明%郭子宽
陳玲珍%劉薇薇%陳嘉榆%餘衛%葉更新%詹昱%巫進明%郭子寬
진령진%류미미%진가유%여위%협경신%첨욱%무진명%곽자관
肝细胞生长因子%髓样组细胞%矽肺%治疗结果
肝細胞生長因子%髓樣組細胞%矽肺%治療結果
간세포생장인자%수양조세포%석폐%치료결과
Hepatocyte growth factor%Myeloid progenitorcell%Silicosis%Treatment outcome
目的 探讨自体骨髓间充质干细胞(BMSCs)移植治疗矽肺的安全性和治疗作用.方法 选取我院确诊的10例矽肺患者,经医学伦理委员会批准,患者签署知情同意书后,无菌抽取患者骨髓液100 ml,体外分离、纯化培养BMSCs,收获第3代BMSCs 5×107个,细胞质量检测合格后,用生理盐水50ml稀释,静脉滴注同输,每周1次,连续3次,其中3例患者采用肝细胞生长因子(HGF)基因修饰的自体BMSCs输注.移植后6个月、9个月,观察患者的临床症状、胸部CT、X线胸片、肺功能、T细胞亚群、血清中IgG、铜蓝蛋白(CP)等指标.结果 治疗9个月后,所有患者咳嗽、咳痰、胸闷症状基本消失；肺功能:最大肺活量(FVC)从治疗前平均(71.2％±17.0％)提高到(84.0％±10.9％),第1秒最大呼气量(FEV1.0)从治疗前平均(67.5％±17.7％)提高到(80.6％±14.9％),与治疗前比较,差异有统计学意义(P＜0.01)；血清中CP和IgG较治疗前明显下降,差异有统计学意义(P＜0.01)；采用HGF基因修饰的自体BMSCs治疗的患者胸片和肺部CT提示有不同程度好转,肺纹理较治疗前减少、清晰,双肺结节影较治疗前缩小,边缘较治疗前清晰,结节影密集及分布均较治疗前有所减少.结论 自体BMSCs移植治疗矽肺对临床症状改善有一定效果,HGF基因修饰的自体BMSCs可使小结节影缩小,略有变淡,肺纹理较治疗前减少.
目的 探討自體骨髓間充質榦細胞(BMSCs)移植治療矽肺的安全性和治療作用.方法 選取我院確診的10例矽肺患者,經醫學倫理委員會批準,患者籤署知情同意書後,無菌抽取患者骨髓液100 ml,體外分離、純化培養BMSCs,收穫第3代BMSCs 5×107箇,細胞質量檢測閤格後,用生理鹽水50ml稀釋,靜脈滴註同輸,每週1次,連續3次,其中3例患者採用肝細胞生長因子(HGF)基因脩飾的自體BMSCs輸註.移植後6箇月、9箇月,觀察患者的臨床癥狀、胸部CT、X線胸片、肺功能、T細胞亞群、血清中IgG、銅藍蛋白(CP)等指標.結果 治療9箇月後,所有患者咳嗽、咳痰、胸悶癥狀基本消失；肺功能:最大肺活量(FVC)從治療前平均(71.2％±17.0％)提高到(84.0％±10.9％),第1秒最大呼氣量(FEV1.0)從治療前平均(67.5％±17.7％)提高到(80.6％±14.9％),與治療前比較,差異有統計學意義(P＜0.01)；血清中CP和IgG較治療前明顯下降,差異有統計學意義(P＜0.01)；採用HGF基因脩飾的自體BMSCs治療的患者胸片和肺部CT提示有不同程度好轉,肺紋理較治療前減少、清晰,雙肺結節影較治療前縮小,邊緣較治療前清晰,結節影密集及分佈均較治療前有所減少.結論 自體BMSCs移植治療矽肺對臨床癥狀改善有一定效果,HGF基因脩飾的自體BMSCs可使小結節影縮小,略有變淡,肺紋理較治療前減少.
목적 탐토자체골수간충질간세포(BMSCs)이식치료석폐적안전성화치료작용.방법 선취아원학진적10례석폐환자,경의학윤리위원회비준,환자첨서지정동의서후,무균추취환자골수액100 ml,체외분리、순화배양BMSCs,수획제3대BMSCs 5×107개,세포질량검측합격후,용생리염수50ml희석,정맥적주동수,매주1차,련속3차,기중3례환자채용간세포생장인자(HGF)기인수식적자체BMSCs수주.이식후6개월、9개월,관찰환자적림상증상、흉부CT、X선흉편、폐공능、T세포아군、혈청중IgG、동람단백(CP)등지표.결과 치료9개월후,소유환자해수、해담、흉민증상기본소실；폐공능:최대폐활량(FVC)종치료전평균(71.2％±17.0％)제고도(84.0％±10.9％),제1초최대호기량(FEV1.0)종치료전평균(67.5％±17.7％)제고도(80.6％±14.9％),여치료전비교,차이유통계학의의(P＜0.01)；혈청중CP화IgG교치료전명현하강,차이유통계학의의(P＜0.01)；채용HGF기인수식적자체BMSCs치료적환자흉편화폐부CT제시유불동정도호전,폐문리교치료전감소、청석,쌍폐결절영교치료전축소,변연교치료전청석,결절영밀집급분포균교치료전유소감소.결론 자체BMSCs이식치료석폐대림상증상개선유일정효과,HGF기인수식적자체BMSCs가사소결절영축소,략유변담,폐문리교치료전감소.
Objective To explore the safety and curative effects of autologous bone marrow-derived mesenchymal stem cells (BMSCs) in the treatment of silicosis.Methods The protocol was approved by the Ethics Committee of the hospital,and ten patients with silicosis who had given written consent were enrolled in this study.BMSCs isolated from 100 ml of bone marrow for each case were purified and cultured,In each case the 3rd generation of qualified BMSCs (5×107) were intravenously administered weekly for 3 weeks.Three cases among 10 patients were treated with BMSCs modified by hepatocyte growth factor (HGF) gene.The clinical symptoms,chest films,chest CT,pulmonary functions,T cells,serum IgG and ceruloplasmin (CP) were observed in 6 or 9 months after treatment.Results No obvious sub-effect was observed in cases treated with BMSCs,the clinical symptoms (such as cough,sputum and chest tightness) basically disappeared in 9 months after treatment.Pulmonary function tests showed that FVC increased from 71.2％±17.0％ to 84.0％±10.9％ (P＜0.01) and FEV10 increased from 67.5％±17.7％ to 80.6％±14.9％ (P＜0.01).The levels of serum CP and IgG significantly decreased (P＜0.01).Further,the chest films and CT in cases treated with autologous BMSCs modified by HGF gene were improved to different extent.Conclusion Treatment with autologous BMSCs modified by HGF gene exhibit a beneficial effect on silicosis.
